Survodutide

What Is Survodutide?

Survodutide is a synthetic dual agonist of the GLP-1 receptor and the glucagon receptor, developed by Boehringer Ingelheim in partnership with Zealand Pharma. Structurally derived from oxyntomodulin and engineered with fatty-acid acylation for a long-acting half-life, it shares its core pharmacology with mazdutide, the other major GLP-1/glucagon dual agonist, with different receptor-binding ratios and pharmacokinetic tuning.

The dual-agonism rationale is the same: GLP-1 agonism drives appetite suppression, delayed gastric emptying, and glucose-dependent insulin release, while glucagon agonism adds hepatic lipid oxidation, elevation of basal metabolic rate, and improved hepatic insulin sensitivity. Survodutide's clinical programme has emphasised metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) as a primary indication alongside obesity, with Phase 2 histology showing resolution of MASH without worsening fibrosis in more than 60% of participants at 48 weeks at the higher doses. The obesity Phase 3 programme is ongoing, and the compound is not approved in any market.